KALV News - Candlesense

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicin...

What impact could this development have on KalVista's partnership or licensing opportunities with larger pharmaceutical firms? Is there any indication that the CHMP positive opinion will expedite the drug's launch timeline in the EU? How might this regulatory update influence institutional and analyst sentiment toward KalVista's stock?

Regulatory

13 days ago

Read more businesswire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted six n...

What is the projected timeline for potential future grants under Nasdaq Listing Rule 5635(c)(4) for KalVista? Will the issuance of these options affect the overall option pool size and future ability to grant equity to other employees? How might the grant influence the overall compensation mix and future hiring incentives at KalVista?

Compensation

20 days ago

Read more businesswire

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Im...

Clinical trials

2 months ago

Read more businesswire

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that ...

Clinical trials

2 months ago

Read more businesswire